LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

97.58 -0.82

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.89

Max

99.15

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	14.17 51.415
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 367M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+10.43% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	993M 20B
Iepriekšējā atvēršanas cena	98.4
Iepriekšējā slēgšanas cena	97.58

Ziņu noskaņojums

By Acuity

25%

75%

111 / 346 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. maijs 22:44 UTC

Iegādes, apvienošanās, pārņemšana

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

2026. g. 14. maijs 22:27 UTC

Iegādes, apvienošanās, pārņemšana

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

2026. g. 14. maijs 22:12 UTC

Peļņas

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

2026. g. 14. maijs 21:52 UTC

Iegādes, apvienošanās, pārņemšana

LVMH to Sell Marc Jacobs

2026. g. 15. maijs 00:00 UTC

Peļņas

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

2026. g. 14. maijs 23:57 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Stake Sales Aim to Secure Funds for Future Investments

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

2026. g. 14. maijs 23:56 UTC

Tirgus saruna

Gold Prices Rise on Strong Demand -- Market Talk

2026. g. 14. maijs 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

2026. g. 14. maijs 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. maijs 23:50 UTC

Tirgus saruna

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

2026. g. 14. maijs 23:47 UTC

Peļņas

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

2026. g. 14. maijs 23:47 UTC

Peļņas

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

2026. g. 14. maijs 23:46 UTC

Peļņas

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

2026. g. 14. maijs 23:46 UTC

Peļņas

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

2026. g. 14. maijs 23:28 UTC

Tirgus saruna

New Zealand's Economy Faltering Amid Shocks -- Market Talk

2026. g. 14. maijs 23:00 UTC

Tirgus saruna

Australia's One Nation Party Leads In The Polls -- Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Court Decision 'Negative But Balanced' for Coles -- Market Talk

2026. g. 14. maijs 22:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 14. maijs 22:35 UTC

Tirgus saruna

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

2026. g. 14. maijs 22:11 UTC

Iegādes, apvienošanās, pārņemšana

LVMH Agrees to Sell Marc Jacobs -- WSJ

2026. g. 14. maijs 22:06 UTC

Tirgus saruna

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

2026. g. 14. maijs 22:04 UTC

Peļņas

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

2026. g. 14. maijs 22:00 UTC

Peļņas

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

2026. g. 14. maijs 21:55 UTC

Peļņas

Nu Holdings 1Q EPS 18c >NU

2026. g. 14. maijs 21:55 UTC

Peļņas

Nu Holdings 1Q Rev $4.97B >NU

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

10.43% augšup

Prognoze 12 mēnešiem

Vidējais 109.13 USD 10.43%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

111 / 346 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation